DIAMEDICA

DiaMedica is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The only universally approved stroke treatment is tissue plasminogen activator (tPA) which can only be administered to patients within 4.5 hours of acute ischemic stroke. However, a urine-derived form of human tissue kallikrein-1 (uKLK1) has been approved in China for up to 48 hours post-stroke by promoting cerebral vascular circu... lation, angiogenesis and inhibiting apoptosis. Published clinical studies have found uKLK1 is also effective in combination with tPA in stroke patients. DiaMedica’s DM199 has been administered to close to 100 patients and demonstrated a safe and well tolerated profile. The Company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. The Company is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases.

#People #Financial #Event #Website #More

DIAMEDICA

Social Links:

Twitter

Industry:

Biopharma Biotechnology Therapeutics

Founded:

2000-01-01

Address:

Minneapolis, Minnesota, United States

Country:

United States

Website Url:

http://www.diamedica.com

Total Employee:

Status:

Active

Contact:

(763)270-0603

Email Addresses:

[email protected]

Total Funding:

87.19 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache

Current Employees Featured

kirsten-gruis_image

Kirsten Gruis
Kirsten Gruis Chief Medical Officer @ DiaMedica
Chief Medical Officer
2022-01-01

not_available_image

Dominic Cundari
Dominic Cundari Chief Commercial Officer @ DiaMedica
Chief Commercial Officer
2022-02-01

not_available_image

Scott Kellen
Scott Kellen Chief Financial Officer @ DiaMedica
Chief Financial Officer
2018-04-01

not_available_image

Wayne Lautt
Wayne Lautt Co-Founder @ DiaMedica
Co-Founder

rick-pauls_image

Rick Pauls
Rick Pauls President & CEO @ DiaMedica
President & CEO
2010-02-01

Founder

not_available_image

Wayne Lautt

Stock Details

Company's stock symbol is NASDAQ:DMAC

Acquisitions List

Date	Company	Article	Price
2010-06-30	Sanomune	Sanomune acquired by DiaMedica	N/A

Investors List

sk-group_image

Key Employee Changes

Date	New article
2022-02-02	DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
2022-01-05	DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer

Official Site Inspections

http://www.diamedica.com Semrush global rank: 2.72 M Semrush visits lastest month: 6.03 K

Host Informations
Whois Informations

Loading ...